Analysis of triclosan inclusion complexes with β-cyclodextrin and its water-soluble polymeric derivative

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 5, 2011, Pages 1030-1039

  Jug, Mario ^a   Kosalec, Ivan ^a   Maestrelli, Francesca ^b   Mura, Paola ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cyclodextrin; ROESY; Solid state analysis; Time kill analysis; Triclosan

Indexed keywords

BETA CYCLODEXTRIN; DRUG CARRIER; EPICHLOROHYDRIN; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; PECTIN; POLYMER; TRICLOSAN;

ANALYTIC METHOD; ANTIMICROBIAL ACTIVITY; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG SOLUBILITY; ENERGY; GRINDING; HYDROPHILICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID STATE; STREPTOCOCCUS MUTANS; X RAY POWDER DIFFRACTION;

BETA-CYCLODEXTRINS; DRUG CARRIERS; EPICHLOROHYDRIN; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PHASE TRANSITION; POLYMERS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TRICLOSAN; WATER; X-RAY DIFFRACTION;

EID: 78751701061     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.12.009     Document Type: Article

References (35)

1. Oliver R.C., Brown L.J., Löe H. Peridontal diseases in the United State population. J. Peridontol. 1998, 69:269-278.
2. Gilbert P., McBain A., Sreenivasan P. Common therapeutic approaches for the control of oral biofilms: microbiological safety and efficiency. Clin. Microbiol. Infect. 2007, 13:17-24.
3. Dinge A., Nagaresenker M. Formulation and evaluation of fast dissolving films for delivery of triclosan to the oral cavity. AAPS Pharm. Sci. Tech. 2008, 9:349-356.
4. Veiga M.D., Merino M., Cirri M., Maestrelli F., Mura P. Comparative study on triclosan interactions in solution and in the solid state with natural and chemically modified cyclodextrins. J. Incl. Phenom. Macrocyclic Chem. 2005, 53:77-83.
5. Stratul S.I., Onisei D., Rusu D. Antimicrobial agents in periodontal disease therapy: rationale and use of the triclosan PVM/MA copolymer in the management of gingivitis. Data from a consensus report. Part I. TMJ 2009, 59:105-108.
6. Loftsson T., Brewster M.E., Másson M. Role of cyclodextrin in improving oral drug delivery. Am. J. Drug Deliv. 2004, 2:261-275.
7. Tommasini S., Raneri D., Ficarra R., Calabrò M.L., Stancanelli R., Ficarra P. Improvement in solubility and dissolution rate of flavonoids by complexation with β-cyclodextrin. J. Pharm. Biomed. Anal. 2004, 35:379-387.
8. Hassan H.A., Al-Marzouqi A.H., Jobe B., Hamza A.H., Ramadan G.A. Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide. J. Pharm. Biomed. Anal. 2007, 45:243-250.
9. Grillo R., De Melo N.F.S., Morales Moraes C., de Lima R., Menezes C.M.S., Ferreira E.I., Rosa A.H., Fernandes Fraceto L. Study of the interaction between hydroxymethylnitrofurazone and 2-hydroxypropyl-β-cyclodextrin. J. Pharm. Biomed. Anal. 2008, 47:295-302.
10. Loftsson T., Leeves N., Bjornsdottir B., Duffy L., Masson M. Effect of cyclodextrin and polymers on triclosan availability and substantivity in toothpastes in vivo. J. Pharm. Sci. 1999, 88:1254-1258.
11. Szente L., Szejtli J. Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 1999, 36:17-28.
12. Layre A.M., Gosselet N.M., Renard E., Sebille B., Amiel C. Comparison of the complexation of cosmetical and pharmaceutical compounds with γ-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin and water soluble β-cyclodextrin-co-epichlorohydrin polymers. J. Incl. Phenom. Macrocyclic Chem. 2002, 43:311-317.
13. Higuchi T., Connors K. Phase solubility techniques. Adv. Anal. Chem. Instrum. 1965, 7:117-212.
14. Paulidou A., Maffeo D., Yannakopoulou K., Mavridis I.M. Crystal structure of the inclusion complex of the antibacterial agent triclosan with cyclomaltoheptaose and NMR study of its molecular encapsulation in positively and negatively charged cyclomaltoheptaose derivates. Carbhoydr. Res. 2008, 343:2634-2640.
15. Azarmi S., Roa W., Löbenberg R. Current perspectives in dissolution tests of conventional and novel dosage forms. Int. J. Pharm. 2007, 328:12-21.
16. National Committee for Laboratory Standards (NCCLS) Reference Method for Broth Dilution Antifungal Susceptibility of Yeasts, Approved Standards M27-A 1997, National Committee for Laboratory Standards, Wayne, PA.
17. Másson M., Sigurdadóttir B.V., Matthíasson K., Loftsson T. Investigation of drug-cyclodextrin complexes by a phase distribution method: some theoretical and practical considerations. Chem. Pharm. Bull. 2005, 53:958-964.
18. Loftsson T., Fridriksdottir H. The effect of water-soluble polymers on the aqueous solubility and complexing abilities of β-cyclodextrin. Int. J. Pharm. 1998, 163:115-121.
19. Faucci M.T., Mura P. Effect of water-soluble polymers on naproxen complexation with natural and chemically-modified-β-cyclodextrins. Drug Dev. Ind. Pharm. 2001, 27:311-319.
20. Maestrelli F., Garcia-Fuentes M., Mura P., Alonso M.J. A new drug nanocarrier consisting of chitosan and hydroxypropylcyclodextrin. Eur. J. Pharm. Biopharm. 2006, 63:79-86.
21. Mura P., Corti G., Maestrelli F., Cirri M. The influence of chitosan on cyclodextrin complexing and solubilizing abilities towards drugs. J. Incl. Phenom. Macrocyclic Chem. 2007, 59:307-313.
22. Mura P., Faucci M.T., Maestrelli F., Furlanetto S., Pinzauti S. Characterization of physicochemical properties of naproxen systems with amorphous β-cyclodextrin-epichlorohydrin polymers. J. Pharm. Biomed. Anal. 2002, 29:1015-1024.
23. Schneider H.J., Hacket F., Rüdiger F.V., Ikeda H. NMR studies and cyclodextrin complexes. Chem. Rev. 1998, 98:1755-1785.
24. de Araújo M.V.G., Vieira E.K.B., Lázaro G.S., Conegero L.S., Almeida L.E., Barreto L.S., da Costa N.B., Gimenez I.F. Sulfadiazine/hydroxypropyl-β-cyclodextrin host-guest system: characterization, phase-solubility and molecular modeling. Bioorg. Med. Chem. 2008, 16:5788-5794.
25. Julian C., Ortosteguis T., Pérez-Cruz P., Sáánchez F., Mendizabal C., Olea-Azar Complexation of morin with tree kinds of cyclodextrin. A thermodynamic and reactivity study. Spectrochim. Acta A 2008, 71:269-275.
26. Duan M., Zhao N., Ossurardóttir I., Thorsteinsson T., Loftsson T. Cyclodextrin solubilization of the antibacterial agents triclosan and tricarban: formation of aggregates and higher-order complexes. Int. J. Pharm. 2005, 297:213-222.
27. Gibaud S., Zirar S.B., Mutzenhardt P., Fries I., Astier A. Melarsoprol-cyclodextrin inclusion complexes. Int. J. Pharm. 2005, 306:107-121.
28. Li J., Xiao H., Li J., Zhong Y.P. Drug carrier systems based on water-soluble cationic β-cyclodextrin polymers. Int. J. Pharm. 2004, 278:329-342.
29. Quan L., Guan Y., Xiao H. Preparation and characterization of inclusion complexes of a cationic β-cyclodextrin polymer with butylparaben or triclosan. Int. J. Pharm. 2008, 357:244-251.
30. Iconomopoulou S.M., Andreopulou A.K., Soto A.J., Kallitsis K., Voyiatzis G.A. Incorporation of low molecular weight biocides into polystirene-divinyl benzene beads with controlled release characteristics. J. Control. Release 2005, 102:223-233.
31. Mura P., Bettinetti G.P., Faucci M.T., Sorrenti M., Negri A. Interaction of naproxen with crystalline and amorphous methylated-β-cyclodextrin in the liquid and solid state. Supramol. Chem. 2001, 12:379-389.
32. Aleem O., Kuchenkar B., Pore Y., Late S. Effect of β-cyclodextrin and hydroxypropylβcyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J. Pharm. Biomed. Anal. 2008, 47:535-540.
33. Misiuk W., Zalewska M. Investigation of inclusion complexes of trazodone HCl with hydroxypropylβcyclodextrin. Carbohydr. Polym. 2009, 77:482-488.
34. Klepser M.A., Ernst E.J., Lewis L.E., Pfaller M.A. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 1998, 42:1207-1212.
35. Pappalardo M.C.S.M., Walderez Szesz M., Martins M.A., Baceti L.B., Bonfietti L.X., Purisco S.U., Baez A.A., Melhem M.S.C. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology. Diagn. Microbiol. Infect. Dis. 2009, 64:146-151.